1. A selective small molecule NOP (ORL-1 receptor) partial agonist for the treatment of anxiety
- Author
-
Michael J. Orsini, Peter J. Connolly, Tina Morgan Ross, Steven A. Middleton, Allen B. Reitz, Gilles Bignan, Malcolm K. Scott, Daniel I. Rosenthal, Jingchun Liu, Doug E. Brenneman, Kathleen A. Battista, and Anil H. Vaidya
- Subjects
medicine.drug_class ,Clinical Biochemistry ,NOP ,Pharmaceutical Science ,Anxiety ,Motor Activity ,Pharmacology ,Biochemistry ,Partial agonist ,Nociceptin Receptor ,Small Molecule Libraries ,Structure-Activity Relationship ,Opioid receptor ,Drug Discovery ,medicine ,Animals ,Inverse agonist ,Spiro Compounds ,Opioid peptide ,Receptor ,Molecular Biology ,Chemistry ,Organic Chemistry ,Small molecule ,Rats ,Disease Models, Animal ,Nociceptin receptor ,Opioid Peptides ,Receptors, Opioid ,Molecular Medicine ,Protein Binding - Abstract
Small molecule (1) has been identified as a selective partial agonist of Opioid Receptor Like-1 (ORL-1) with potential utility for the treatment of anxiety and other disorders. Nociceptin (orphanin FQ) is an endogenous peptide ligand that binds to ORL-1, however it does not bind the classical δ, μ and κ opioid receptors with high affinity. The synthesis of 1 involved using a molecular diversity approach, to rapidly advance a library of compounds for biological testing. A lead selective potent partial agonist (35-fold ORL-1/Mu) progressed to ORL-1 (NOP or OP4) proof of concept testing in advanced studies. The synthetic approach and biological data for the related chemical series will be presented.
- Published
- 2015